Pfizer Expects $54 Billion in 2022 Sales on Covid Vaccine

Pfizer Inc. recorded quarterly profits above analysts’ expectations, and its revenues rose, but less than estimates, while it expects to record strong sales of its vaccine and treatment for the Coronavirus.

Pfizer’s fourth-quarter revenue more than doubled overall to $23.84 billion year-over-year, driven by $12.5 billion in sales of its Covid vaccine

Pfizer’s miss on revenue was driven by lackluster sales in its internal medicine and hospital segments. Fourth-quarter internal medicine sales fell 3% year-over-year to $2.24 billion, while hospital sales were largely flat at $1.88 billion compared to the same quarter in 2020. Pfizer’s oncology sales grew 7% to $3.24 billion compared with the same three months in the previous year.